Sarcoma represents a highly heterogeneous group of tumours. We report here the first unbiased and systematic search for gene fusions combined with unsupervised expression analysis of a series of 184 small round cell sarcomas. Fusion genes were detected in 59% of samples, with half of them being observed recurrently. We identified biologically homogeneous groups of tumours such as the CIC-fused (to DUX4, FOXO4 or NUTM1) and BCOR-rearranged (BCOR -CCNB3, BCOR -MAML3, ZC3H7B-BCOR, and BCOR internal duplication) tumour groups. VGLL2-fused tumours represented a more biologically and pathologically heterogeneous group. This study also refined the characteristics of some entities such as EWSR1-PATZ1 spindle cell sarcoma or FUS-NFATC2 bone tumours that are different from EWSR1-NFATC2 tumours and transcriptionally resemble CIC-fused tumour entities. We also describe a completely novel group of epithelioid and spindle-cell rhabdomyosarcomas characterized by EWSR1-or FUS-TFCP2 fusions. Finally, expression data identified some potentially new therapeutic targets or pathways.
Introduction
Small round cell sarcoma is a heterogeneous group of tumours mostly affecting children and young adults and characterised by an overall poor prognosis [1] . They remain challenging for pathologists because those tumours share overlapping morphological and immunophenotypical features. The identification of specific fusion transcripts has considerably improved their diagnosis as many subtypes are characterised by a specific fusion gene, such as EWSR1/FUS-ETS, SS18-SSX, and PAX-FOXO1 fusions in Ewing sarcoma
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As a result, diagnostic evaluation of specific chromosome translocations by FISH or of the resulting fusion transcripts by RT-PCR has become an asset for the molecular assessment of small round cell sarcoma. However, a number of sarcomas remain uncharacterised, raising both diagnostic and therapeutic issues.
In the present study, we report RNA sequencing of 184 small round cell sarcoma samples from three different cohorts. By applying several fusion algorithms and performing unsupervised clustering analysis, we were able to show that recurrent fusions define homogeneous groups of tumours based on pathological features and expression profile analyses, including FUS-NFATC2-positive, EWSR1-PATZ1-positive, CIC-fused, and BCOR-rearranged tumours. We also identified a new epithelioid rhabdomyosarcoma group characterised by an EWSR1-TFCP2 or FUS-TFCP2 fusion gene. Finally, we propose genes and pathways that are expressed specifically in a variety of different entities that may serve as biomarkers or potential therapeutic targets.
Materials and methods

Tumour samples
Tumour samples were chosen based on their pathological diagnosis either as unclassified sarcoma or as known sarcoma that did not carry pathognomonic genetic aberrations or suspicious for sarcoma with simple genetic or monomorphic features (supplementary material, Figure S1 ). Samples were used in accordance with the French Biobank legislation.
Paired-end RNA sequencing
Total RNAs were isolated from crushed frozen tumours using a Trizol reagent kit (Life Technologies, Carlsbad, CA, USA). Library constructions were performed following the TruSeq Stranded mRNA LS protocol (Illumina, San Diego, CA, USA). Sequencing was performed on either HiSeq 2500 (100 nt paired-end) or NextSeq 500 (150 nt paired-end) Illumina sequencing machines. All fastq files have been deposited in the European Genome-phenome Archive (https://www.ebi .ac.uk/ega/studies/EGAS00001002189). Raw sequencing files of SMARCA4-DTS and MRT control samples had previously been deposited in the Sequence Read Archive (#SRP052896).
Bioinformatics analyses
For fusion gene discovery, sequencing reads were injected into both the deFuse tools [8] and the FusionMap tool [9] with hg19 genome as reference. Only fusion transcripts supported by both tools with at least two split reads (and three spanning pairs for defuse) were considered. Gene expression values were extracted by Kallisto v0.42.5 [10] with GRCh38 release 79 genome annotation. Clustering, BGA, PCA, and t-SNE were computed using R packages Cluster v2.0.3, made4 version 1.44.0, FactoMiner v1.31.4, and Rtsne version 0.10, respectively. Gene ontology analyses were performed online (https://david.ncifcrf.gov/) using the tool DAVID v6.7 [11] .
Fusion validation
PCR amplification of the fusion point using specifically designed primers and 50 ng of cDNA was then performed using AmpliTaq Gold ® DNA Polymerase with Buffer II (Thermo Fisher Scientific, Waltham, MA, USA) prior to Sanger sequencing on an Applied 3500XL Genetic Analyzer.
Immunohistochemistry
Immunohistochemistry was performed using the following antibodies and methods: NUTM1 (C52B1; Cell Signaling Technology, Danvers, MA, USA; dilution 1:50) and ALK (5A4,; Cell Signaling Technology; dilution 1:50). IHC was performed on a Ventana BenchMark platform with Cell Conditioning Solution 1 pretreatment. NUTM1 was incubated for 56 min and ALK for 80 min prior to being revealed with the ultraView Universal DAB Detection Kit. ETV4 (clone 16; Santa Cruz Biotechnology, Santa Cruz, CA, USA; dilution 1:15). IHC was performed overnight at 4 ∘ C, following preheating at 98 ∘ C for 30 min in Tris buffer, pH 9, and was revealed with the REAL EnVision kit (Dako, Glostrup, Denmark).
Results
In molecular diagnostic routine, primitive small round or spindle cell sarcomas are systematically tested for the most common fusion genes using multiplexed qPCR (supplementary material, Table S1 ). In the present study, we performed whole transcriptome sequencing to investigate its efficacy for proper tumour classification. Our investigation cohort was composed of 94 samples randomly selected from about 700 retrospective samples in which no common fusion gene could be identified by standard diagnostic investigation (see the general scheme of the analysis in the supplementary material, Figure S1 ). We first investigated the presence of gene fusions, and the retained fusion candidates were subsequently validated and searched for within the remaining available samples (around 600 cases) using specific RT-PCR assay. The new cases thus identified were also RNA-sequenced and generated our follow-up cohort (12 samples). Basic clinical data, initial diagnosis, and results of molecular analyses for all the 184 cases sequenced in this study are summarised in the supplementary material, Table S2 . We next performed expression profile analyses that we compared using t-distributed stochastic neighbour embedding (t-SNE) [12] and unsupervised clustering analyses ( Figure 1A , Figure S2 ) with a subset of 78 well-defined cases making up our control cohort. For each group, differential expression analyses against each of all the other tumour types were performed. The top variant genes are listed in the supplementary material, Table S3 , together with ontology enrichment and gene set enrichment analyses (GSEA).
A fusion gene could be identified in almost 3/5 of the investigation cohort samples
We identified fusion genes in 55 out of the 94 tumours of the investigation cohort. Except for one case (SARC036) for which numerous fusions were found on chromosome 1, suggestive of chromothripsis, the mean number of fusion events detected per sample was 1.8. Forty samples carried a single fusion gene, while multiple (2-9) gene fusions were detected in 14 samples (supplementary material, Table S2 ). All fusion genes were subsequently confirmed by RT-PCR and Sanger sequencing.
Most of the RNAseq fusion-positive samples (26/55) expressed previously described fusion genes that were not included in our RT-PCR routine procedure, namely single cases of each of the following fusions: Table S2 ).
Novel fusions were detected in 29 samples (supplementary material, Table S2 ). Two cases presented variants of known fusions: UXT-TFE3, a variant of the ASPSCR1-or SFPQ-TFE3 fusions found in alveolar soft part sarcomas and renal cell carcinoma; and IKBKG-ALK, a new variant among the numerous ALK fusions found in inflammatory myofibroblastic tumours. In two cases, we identified a completely new fusion between EWSR1 or FUS and TFCP2. Eleven samples harboured previously undescribed fusions, involving genes relevant for tumourigenesis, but for which no additional sample could be identified during the RT-PCR screen. These fusions were then considered as private to their respective tumour. Finally, in the remaining 14 fusion-positive cases, we were unable to propose a definitive driver event, due to our lack of knowledge on the implication in cancer of the fused genes.
Emerging VGLL2 -NCOA2/CITED, CIC-fused, and BCOR-rearranged sarcoma subtypes A total of seven samples harbouring a VGLL2 fusion with either NCOA2 (n = 6) or CITED (n = 1) were identified (supplementary material, Figure S3A ), with two samples forming a primary/relapse couple (SARC070_Primary and SARC070_Relapse). These fusion genes characterised tumours occurring in very young children (below 5 years old), as previously described [13] . A centralized review of the cases highlighted two subtypes with specific pathological aspects. In three cases (SARC061, SARC065, and SARC070_primary), the tumours were composed of a large amount of fibrous stroma with scarce tumour cells ( Figure 2A ). Tumour cells presented neither atypia nor abnormal mitotic figures. They were negative for desmin, whereas few cells (below 1%) showed nuclear positivity for myogenin. Fewer than 25% of cells were Ki67-positive. In contrast, in the four other cases (SARC070 at relapse, SARC085, SARC088, and SARC102), the cellular mass was far denser, with cells presenting numerous atypia and mitoses. Myogenin staining was strongly positive in around 10% of cells, and desmin and Ki67 immunoreactivity was displayed by over 30% of tumour cells ( Figure 2B ). Consistent with this histological heterogeneity, t-SNE analysis and unsupervised clustering revealed a relatively disparate group of tumours ( Figure 1A and supplementary material, Figure S2A ), whose samples could further be separated according to the histology, when different clustering conditions were applied (supplementary material, Figure S2C , D). When considering these two histological subtypes separately, it appeared that the 'fibrous' subtype was enriched in immune/inflammatory response genes, while the 'dense' subtype was enriched in cell cycle/proliferation genes (supplementary material, Table S3 ). Supervised group comparisons and between-group analyses (BGAs) indicated that VGLL2-fused tumours expressed numerous muscle-related genes as well as genes involved in extracellular matrix and in the epithelial-mesenchymal transition process. Despite clear positivity for muscle differentiation markers, none of the two subtypes clustered with rhabdomyosarcoma samples.
A total of five CIC-NUTM1 (supplementary material, Figure S3B ) fusions were retrieved. All but one case were observed in young children, at various locations (supplementary material, Table S2 ). Tumours harbouring CIC-NUTM1 fusion clustered tightly with the other CIC-DUX4-positive or CIC -FOXO4-positive samples ( Figure 1 ). All of these tumours overexpressed ETS family members of the PEA3 type [5, 14, 15] as well as a variety of secreted and matrix protein genes such as VGF, BMP2, glypican 3/4, NRG1, PTX3, pleiotrophin (PTN), and spondins. GSEA revealed enrichment in genes of the extracellular matrix but also in genes overlapping proliferation/response to drug/immune response categories (supplementary material, Table S3 ).
The seven samples presenting a rearrangement of BCOR, including BCOR-MAML3 or ZC3H7B-BCOR fusions [16] and internal tandem duplication (ITD) [17] [18] [19] (supplementary material, Figure S3C ), grouped together with the BCOR-CCNB3-positive samples from the control cohort, describing a very-well Figure S2B for the full annotated cluster).
defined cluster. These samples also shared some pathological features, as previously described [17] . Among the most significantly enriched gene ontologies for this BCOR-rearranged group were 'developmental protein' and 'homeobox' (supplementary material, Table S3 ) with strong overexpression of HOX-A, -B, -C, and -D family genes as well as HMX1, PITX1, ALX4 or DLX1. More specifically, we observed very strong gene sets and ontology enrichments for the morphogenesis, development, and differentiation of neurons, and for skeletal system development. Finally, different genes encoding membrane receptors including RET, FGFR2/3, EGFR, PDGFRA, NTRK3, KIT, and NGFR were also highly and constantly overexpressed in these tumours and may hence constitute actionable target genes. 
Identification of a FUS-NFATC2 fusion gene in a new bone tumour entity transcriptionally distinct from EWSR1-NFATC2-positive tumours
We identified FUS-NFATC2 fusion genes in three tumours of the femurs of adult patients (median age 38.3 years), like the only case described in the literature [17] . Tumours displayed areas composed of round tumour cells arranged in sheets or short fascicles. Tumour cells were embedded in a variably myxoid stroma ( Figure 3A) . A focal haemangiopericytic vascular network was present in all cases ( Figure 3B ). More distinctively, these tumours harboured focal myxohyaline foci, raising suspicion of cartilaginous 
EWSR1-PATZ1 fusion gene is found in a new tumour group unrelated to any other EWSR1-fused tumour
While only single cases of tumour carrying an EWSR1-PATZ1 fusion have been previously reported [21] [22] [23] , in our cohorts we identified a total of five cases ( Figure 4A and supplementary material, Figure  S3D ). All tumours were from soft tissues and occurred across a very broad age range (from 0.9 to 68.5 years). Centralized pathological review of three cases indicated three different morphological aspects ( Figure 4B ): (i) a first tumour was composed of bundles of relatively monomorphic spindle cells with an eosinophilic cytoplasm and enlarged hyperchromatic nuclei; (ii) a second case consisted of a diffuse proliferation with several vessels forming a 'haemangioma-like' vasculature. Tumour cells were mostly round and focally spindle, with scant cytoplasm and an enlarged nucleus containing one nucleolus; (iii) the last case resided in a diffuse proliferation of spindle cells displaying an eosinophilic cytoplasm and oval nuclei with an irregular chromatin distribution with one or several nucleoli. Some nests of epithelioid cells with abundant, eosinophilic or clear, cytoplasm and atypical nuclei could be seen. Nevertheless, two features were observed consistently: a fibrous stroma and the presence of at least one component of spindle-shaped cells. All cases were negative for EMA and AE1/AE3 and inconsistent for PS100, cytoplasmic CD99, and vimentin staining. Ki67 was high (between 20% and 70%). In agreement with this heterogeneous histological presentation, the proposed diagnoses for EWSR1-PATZ1-positive tumours were quite variable, including unclassified spindle cell sarcoma, myxoid liposarcoma, Ewing-like sarcoma, and unclassified malignant neuroectodermal tumours. Nevertheless, all five tumours clustered tightly together and away from other EWSR1-fused tumours, indicative of a transcriptionally different entity. GSEA-identified enrichment of genes correlated with SMARCA2 expression in prostate cancer (supplementary material, Table S3 ). Figure  S2 ). EWSR1/FUS-TFCP2-positive tumours arose in young adult females (age range 16-38 years) and developed in either the pelvic region, the chest wall or the sphenoid bone. All three tumours were extremely aggressive, as patient survival did not exceed 5 months. Upon review, all three tumours were composed of an epithelioid proliferation arranged in small sheets or short fascicles. Tumour cells presented monotonous round nuclei with high-grade features and prominent nucleoli ( Figure 5B ). They were associated with variable amounts of fibrous stroma with focal sclerosing areas that were present in all cases. The three tumours stained positive for desmin, MYOD1, and myogenin. Gene expression profile comparison confirmed strong expression of MYOD1 and DES as well as impressive overexpression of TERT and ALK (supplementary material, Figure S4B ), the latter being heterogeneously expressed with both cytoplasmic and membranous staining ( Figure 5B) . In silico functional analyses highlighted T-cell immune response as well as keratin intermediate filament enrichment (supplementary material, Table S3 ). Altogether, the observation of positivity for both muscle and epithelial markers suggests that this EWSR1/FUS-TFCP2 fusion defines a new aggressive 'epithelioid rhabdomyosarcoma' entity.
Expression profiling reveals distinct transcriptomic patterns and potential biomarkers
Supervised group comparisons and between-group analyses (BGAs) highlighted genes specifically expressed in the molecularly defined entities ( Figure 6 and supplementary material, Table S3 ). More specifically, crossing pairwise differential analysis and BGA analysis, we identified genes that were specifically expressed in each tumour type including VGLL2-fused tumours (LANCL2), CIC-fused tumours (ETV4), BCOR-rearranged (HES7), FUS-NFATC2-positive sarcomas (CD8B), EWSR1-PATZ1-positive tumours (GPR12), and FET-TFCP2-positive tumours (REQL), but also for almost all of the other tumour entities (supplementary material, Figure S5 ).
Discussion
We have used RNA sequencing to investigate unclassified small round or spindle cell sarcomas. We first confirm that sarcomas, like haematological malignancies [24] , demonstrate a high incidence of gene fusions compared with carcinomas. In this respect, it is noteworthy that the mesenchyme, from which sarcomas are derived, and haematopoiesis, from which leukaemias and lymphomas arise, both originate from the mesoderm. One hypothesis may rely on the activity of specific recombinases in mesodermal-derived tissues. In this respect, we can mention the role of the RAG1 recombinase in the generation of lymphoma-specific translocations [25] and the recently suspected role of the PGBD5 recombinase in malignant rhabdoid tumours [26] .
Combining fusion gene discovery and expression profiling, our analysis resulted in the delineation of biologically homogeneous groups of tumours. While the CIC-NUTM1 fusion was discovered as a new brain tumour entity [14] , we show here that they are encompassed in a homogeneous CIC-fused group of tumours together with CIC-DUX4-and CIC-FOXO4-positive samples [27] . The overexpression of genes of the PEA3 type of the ETS family observed in all CIC-fused samples is known to be a consequence of a loss of function of CIC [28] , which was also involved in resistance to MAPK inhibitors [28, 29] or in the promotion of metastasis [30] . Further analyses should confirm whether a dominant negative effect on wild-type CIC is a consequence of CIC fusions and if it may be correlated with the aggressiveness of CIC-fused tumours. The BCOR-rearranged group of tumours includes various BCOR-fusion genes and BCOR-ITD. BCOR-ITD was described in CCSK [19] , in a new brain tumour entity CNS HGNET-BCOR [14] , and in soft tissue undifferentiated round cell sarcoma of infancy sharing strong similarities with CCSK [17] . This homogeneous biological entity may also present clinical specificities depending on the type of genetic lesions. Indeed, while BCOR-CCNB3 was exclusively observed in bone, BCOR-ITD was only observed in soft tissues. BCOR rearrangements may lead to an abnormal activity of the non-conventional polycomb repressive BCOR (or PRC1.1) complex [31] . In this regard, the observation that BCOR rearrangements are associated with increased expression of genes correlated with SMARCA2 expression (supplementary material, Table S3 ) may suggest that impairment of PRC1.1 activity leads to an increased activity of the antagonist SWI/SNF complex. Thanks to a unique collection, we found several samples carrying FUS-NFATC2 or EWSR1-PATZ1 fusions, which formed tight groups. FUS-NFATC2-positive tumours present different morphologies but with features rather reminiscent of CIC-fused tumours and are definitively different from EWSR1-NFATC2-positive tumours. EWSR1-PATZ1 tumours present relatively divergent cell morphologies, rendering their pathological identification challenging, though areas of spindle cells found in all three samples may guide pathologists during diagnosis. The identification of more cases is nevertheless mandatory to improve the characterisation of these ultra-rare FET-fused sarcomas.
We also describe here a new entity carrying an EWSR1-or FUS-TFCP2 fusion gene. TFCP2 (also known as LSF or LBP1) does not resemble any of the usual FET-fusion partners. It was first described as an activator of the late SV40 promoter and later found to bind globins and HIV-1 promoters [32, 33] . TFCP2 is ubiquitously expressed and plays determinant roles in lineage-specific gene expression and cell cycle regulation [34] . Potential involvement of TFCP2 in oncogenesis has been suggested and may depend on tumour type. In hepatocellular carcinomas, TFCP2 is overexpressed [35] and its inhibition by small molecules leads to cell cycle arrest [36] , whereas in skin melanoma, TFCP2 is underexpressed and its re-expression induces growth arrest [37] . Interestingly, in addition to the expression of MYOD1 (supplementary material, Table S3 ), a number of up-regulated genes in these FUS/EWSR1-TFCP2-positive tumours are involved in muscle biology (such as cholinergic receptor nicotinic subunit alpha 1, delta and gamma, and sarcoglycan alpha). This may suggest either a muscle cellular origin of these tumours or a muscle differentiation programme triggered by the fusion protein. Consistent with the genes expressed, pathological review confirmed that TFCP2-rearranged tumours were an epithelioid variant of rhabdomyosarcoma, although the morphological spectrum of these tumours needs to be assessed on a larger scale. Despite a common muscle phenotype, these samples do not cluster together with other rhabdomyosarcomas. Considering potential therapeutic targets, it is noteworthy that ALK and TERT are highly expressed in these tumours. Moreover, recently developed small molecules impeding the DNA-binding activity of TFCP2 [36, 38] , which remains in the fusion protein, might also be effective in hindering EWSR1-TFCP2 binding and possibly in inhibiting the development of these very aggressive tumours.
Samples carrying VGLL2-NCOA2 or VGLL2-CITED2 fusion genes demonstrate some transcriptome heterogeneity related to two different histological subtypes: one presenting only a few tumour cells surrounded by fibrous stroma, rather suggestive of relatively benign tumours, and the other with a spindle cell rhabdomyosarcoma-like morphology similar to that reported [13] and exhibiting expression profiles enriched in cell cycle genes. Interestingly, one fibrous tumour and one rhabdomyosarcoma-like tumour represented the primary and the relapse tumours from the same patient, respectively. It is therefore likely that the rhabdomyosarcoma-like tumour represents a more aggressive evolution of the fibrous tumour. Further analyses including exome sequencing of the two tumours may enable the identification of additional genetic mutations accounting for this evolution.
In addition to the fundamental role of expert surgical pathology, molecular analysis is now becoming an integral part of the diagnosis of small round cell tumours, in particular for resolving frequent diagnostic dilemmas. With the increase of sarcoma subclasses, it becomes difficult for the pathologist to ascertain a precise diagnosis in a reliable and cost-effective way. In this respect, and depending on the expertise and technical availabilities at each pathology department, two molecular approaches may be proposed. One may rely on the design of a specific panel of genes, based on our selection of genes that are specifically expressed in each tumour group, tested in a simple assay (e.g. using Nanostring technology).
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Alternatively, thanks to the constant decrease of whole transcriptome costs and the availability of robust bioinformatics tools, we strongly believe that RNA sequencing is a key approach. Indeed, our work indicates that the convergent information from gene fusion detection and expression profiles-based clustering is extremely powerful to identify biologically homogeneous groups of tumours. Hence, in the short term, RNA sequencing is expected to constitute a mandatory methodology for an efficient molecular diagnosis of sarcoma, a requirement recently proposed in the GENSARC study [39] . Such a precise subgrouping of sarcomas is essential (i) to investigate the clinical characteristics of each subgroup, particularly regarding the risk of evolution and response to current treatment options; (ii) to identify new therapeutic opportunities, as potentially ALK overexpression in EWSR1/FUS-TFCP2 sarcomas; (iii) to construct relevant animal models to design robust pre-clinical studies; and (iv) to design highly specific assays to monitor circulating cell and tumour DNA during treatment. Further increasing the number of samples, within large international consortia, is essential to identify groups of tumours of sufficient size to enable robust conclusions and to allow the collection of otherwise 'orphan' samples. Figure S1 . Constitution of the cohorts Table S2 . Description of the samples from the three cohorts Table S3 . Differentially expressed genes in the BGA and supervised analyses and Gene ontology/GSEA enrichment for all sarcomas subtypes Table S4 . Differentially expressed genes and gene ontology enrichment for FUS-NFATC2-positive versus EWSR1-NFATC2-positive tumours
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